Esperion Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Esperion Therapeutics
ESPR Stock  USD 3.46  0.07  2.06%   
Esperion Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Esperion Therapeutics' valuation are provided below:
Gross Profit
131.9 M
Profit Margin
(0.35)
Market Capitalization
827.2 M
Enterprise Value Revenue
3.4282
Revenue
303.8 M
There are over one hundred nineteen available fundamental signals for Esperion Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to verify Esperion Therapeutics' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/12/2026, Market Cap is likely to grow to about 510.9 M, while Enterprise Value is likely to drop slightly above 564.5 M.

Esperion Therapeutics Total Revenue

377.84 Million

Check Esperion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Esperion Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 76.1 K, Interest Expense of 71.5 M or Gross Profit of 341.8 M, as well as many indicators such as Price To Sales Ratio of 1.35, Dividend Yield of 0.0 or Days Sales Outstanding of 84.78. Esperion financial statements analysis is a perfect complement when working with Esperion Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Esperion Stock
Check out the analysis of Esperion Therapeutics Correlation against competitors.
To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Esperion Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets415.2 M395.4 M221.1 M
Slightly volatile
Short and Long Term Debt Total713.9 M679.9 M193.3 M
Slightly volatile
Other Current Liabilities98 M93.3 M33.7 M
Slightly volatile
Total Current Liabilities297.3 M283.2 M85.8 M
Slightly volatile
Property Plant And Equipment Net7 M6.6 M2.6 M
Slightly volatile
Accounts Payable62.4 M59.4 M23.8 M
Slightly volatile
Cash95 M166.5 M96.2 M
Slightly volatile
Non Current Assets Total6.4 M6.7 M19.5 M
Pretty Stable
Cash And Short Term Investments103.3 M166.5 M104.4 M
Slightly volatile
Common Stock Total Equity90.6 K86.2 K38.4 K
Slightly volatile
Common Stock Shares Outstanding226 M215.3 M60.5 M
Slightly volatile
Other Current Assets22.5 M21.4 M7.7 M
Slightly volatile
Total Liabilities884.5 M842.4 M299.4 M
Slightly volatile
Property Plant And Equipment Gross9.5 M9 M2.9 M
Slightly volatile
Total Current Assets408.1 M388.7 M201.5 M
Slightly volatile
Short Term Debt126.7 M120.6 M25.3 M
Slightly volatile
Common Stock236.7 K225.4 K64.8 K
Slightly volatile
Intangible Assets47.9 K50.4 K257.5 K
Slightly volatile
Other Liabilities542.1 K570.6 K1.2 M
Slightly volatile
Property Plant Equipment179.2 K188.6 K462.7 K
Very volatile
Current Deferred Revenue10.3 M9.8 M4.3 M
Slightly volatile
Capital Surpluse676.3 M1.2 B625 M
Slightly volatile
Long Term Debt Total216.6 M206.3 M110.8 M
Slightly volatile
Short and Long Term Debt65.9 M62.8 M24.7 M
Slightly volatile
Net Working Capital119.3 M82.6 M152.4 M
Slightly volatile
Capital Stock236.7 K225.4 K71.1 K
Slightly volatile
Capital Lease Obligations3.7 M6.1 M2.6 M
Slightly volatile
Non Current Liabilities Other145.1 M282.9 M139.7 M
Slightly volatile
Net Receivables96.8 M92.2 M30 M
Slightly volatile

Esperion Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses335.6 M319.6 M173.4 M
Slightly volatile
Research Development74.4 M53.2 M75.3 M
Slightly volatile
Total Operating Expenses135.7 M240.7 M147.8 M
Slightly volatile
Selling General Administrative166.1 M158.2 M71.9 M
Slightly volatile
Non Operating Income Net Other2.3 M3 M1.7 M
Slightly volatile
Reconciled Depreciation53.9 K56.7 K278.3 K
Pretty Stable
Interest Income3.5 M4 M4.3 M
Slightly volatile
Selling And Marketing Expenses18.8 M29.3 M19.2 M
Pretty Stable

Esperion Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow87.8 M94.6 M86.6 M
Slightly volatile
End Period Cash Flow98.2 M166.5 M99.4 M
Slightly volatile
Stock Based Compensation15.2 M13.8 M13.1 M
Slightly volatile
Change To Netincome18.7 M17.5 M14.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.351.431.3 K
Slightly volatile
Days Sales Outstanding84.7879.2252.5047
Slightly volatile
Average Payables775.1 K1.2 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue0.03090.03250.0979
Slightly volatile
Inventory Turnover0.430.650.3103
Slightly volatile
Days Of Inventory On Hand1.1 K5781.8 K
Slightly volatile
Payables Turnover1.261.20.5557
Slightly volatile
Sales General And Administrative To Revenue0.210.370.2351
Slightly volatile
Research And Ddevelopement To Revenue0.150.16641
Slightly volatile
Capex To Revenue0.0010.001139.4456
Slightly volatile
Cash Per Share0.840.893.2752
Very volatile
Days Payables Outstanding3003167.1 K
Very volatile
Income Quality0.840.530.7362
Slightly volatile
Intangibles To Total Assets2.0E-42.0E-40.0047
Slightly volatile
Current Ratio1.51.586.9248
Slightly volatile
Receivables Turnover6.724.7713.2791
Slightly volatile
Capex Per Share0.00190.00190.1047
Slightly volatile
Revenue Per Share1.942.0460.8946
Slightly volatile
Interest Debt Per Share1.943.132.5793
Slightly volatile
Debt To Assets1.621.550.9715
Pretty Stable
Operating Cycle1.2 K6791.9 K
Slightly volatile
Days Of Payables Outstanding3003167.1 K
Very volatile
Quick Ratio1.081.146.7669
Slightly volatile
Net Income Per E B T0.70.790.8633
Slightly volatile
Cash Ratio0.640.683.69
Slightly volatile
Days Of Inventory Outstanding1.1 K5781.8 K
Slightly volatile
Days Of Sales Outstanding84.7879.2252.5047
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.171.0458
Pretty Stable
Fixed Asset Turnover62.9566.2711 K
Slightly volatile
Debt Ratio1.621.550.9715
Pretty Stable
Price Sales Ratio1.351.431.3 K
Slightly volatile
Asset Turnover1.061.1111.9225
Slightly volatile
Gross Profit Margin0.890.910.9205
Slightly volatile

Esperion Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap510.9 M370.6 M651.1 M
Very volatile
Enterprise Value564.5 M772.4 M711 M
Slightly volatile

Esperion Fundamental Market Drivers

Forward Price Earnings5.9666
Cash And Short Term Investments144.8 M

Esperion Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Esperion Therapeutics Financial Statements

Esperion Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Esperion Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Esperion Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Esperion Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue9.8 M10.3 M
Cost Of Revenue78.9 M39.7 M
Total Revenue299.1 M377.8 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.37  0.21 
Research And Ddevelopement To Revenue 0.16  0.15 
Revenue Per Share 2.04  1.94 
Ebit Per Revenue 0.19  0.20 

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Esperion Stock

  0.47KRRO Frequency TherapeuticsPairCorr
  0.39EVGN EvogenePairCorr
  0.34IMRN Immuron Ltd ADRPairCorr
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY